Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin.

Clicks: 159
ID: 119378
1993
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #94 of 105 articles by views in Antimicrobial agents and chemotherapy

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
We performed a randomized, controlled trial of intravenous immune globulin (respiratory syncytial virus [RSV] neutralizing [Nt] antibody titer of 1:950 in 5% solution) to evaluate protection against RSV-induced disease over two respiratory virus seasons. ...
Reference Key
snydman1993antimicrobialcontrolled Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors H C Meissner, D R Fulton, J R Groothuis, R L Geggel, G R Marx, V G Hemming, T Hougen, D R Snydman, H C Meissner, D R Fulton, J R Groothuis, R L Geggel, G R Marx, V G Hemming, T Hougen, D R Snydman
Are you one of these authors? Claim your profile
Journal Antimicrobial agents and chemotherapy
Year 1993
DOI
10.1128/aac.37.8.1655
URL
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC188036/
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.